^
    4years
    A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (ASH 2021)
    A total of 17 patients were enrolled; median age was 72 (range, 34-88) years and 47% (8/17) of patients were ≥75 years. Median number of prior lines of therapy was 2 (range, 1-6). Overall response rate was 24% with a CR rate of 12%.
    Clinical • P1 data • IO biomarker
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    STAT3 expression
    |
    Calquence (acalabrutinib) • CAR T-cell therapy • danvatirsen (AZD9150)
    4years
    Clinical and Biological Effects of Combined CD27 and CD20 Antibody Therapy in Relapsed/Refractory B-Cell Lymphoma: The Riva Trial (ASH 2021)
    Combined rituximab and varlilumab administration is safe in relapsed/refractory B-cell lymphomas and demonstrates efficacy in patients with T-cell activated tumours. Transcriptomic analysis of pre- and post-treatment samples confirms that varlilumab has in vivo agonistic activity. B-cell depletion by rituximab is dependent on intratumoral macrophages and varlilumab induces myeloid cell activation via a T-cell dependent, MIF signalling pathway.
    Clinical
    |
    CD8 (cluster of differentiation 8) • CD74 (CD74 Molecule) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD44 (CD44 Molecule) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • CD86 (CD86 Molecule)
    |
    Rituxan (rituximab) • varlilumab (CDX 1127) • CAR T-cell therapy